JP2003500454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500454A5 JP2003500454A5 JP2000620976A JP2000620976A JP2003500454A5 JP 2003500454 A5 JP2003500454 A5 JP 2003500454A5 JP 2000620976 A JP2000620976 A JP 2000620976A JP 2000620976 A JP2000620976 A JP 2000620976A JP 2003500454 A5 JP2003500454 A5 JP 2003500454A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cyclosporin
- present
- compositions
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 33
- 229960001265 ciclosporin Drugs 0.000 description 17
- 229930182912 cyclosporin Natural products 0.000 description 16
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 15
- 108010036949 Cyclosporine Proteins 0.000 description 15
- 229930105110 Cyclosporin A Natural products 0.000 description 13
- -1 fatty acid esters Chemical class 0.000 description 13
- 239000004530 micro-emulsion Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 238000007127 saponification reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- SEBABJIIUXZALO-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCCCCCCC(O)C(O)=O SEBABJIIUXZALO-UHFFFAOYSA-N 0.000 description 1
- JZSMZIOJUHECHW-GTJZZHROSA-N 2-hydroxypropyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(C)O JZSMZIOJUHECHW-GTJZZHROSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000640882 Condea Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 125000001020 α-tocopherol group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9912476.0A GB9912476D0 (en) | 1999-05-28 | 1999-05-28 | Organic compounds |
| GB9912476.0 | 1999-05-28 | ||
| PCT/EP2000/004829 WO2000072867A2 (en) | 1999-05-28 | 2000-05-26 | Substantially oil-free cyclosporin compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500454A JP2003500454A (ja) | 2003-01-07 |
| JP2003500454A5 true JP2003500454A5 (cg-RX-API-DMAC10.html) | 2007-07-19 |
Family
ID=10854362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620976A Pending JP2003500454A (ja) | 1999-05-28 | 2000-05-26 | 実質的にオイルフリーのシクロスポリン組成物 |
Country Status (26)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT988046E (pt) * | 1997-01-30 | 2004-12-31 | Novartis Ag | Composicoes farmaceuticas sem oleo contendo ciclosporina a |
| IL143604A0 (en) | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
| GB9912476D0 (en) | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
| AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| US20050129718A1 (en) * | 2001-12-20 | 2005-06-16 | Sherman Bernard C. | Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| CA2518265A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| JP2005255677A (ja) * | 2004-02-12 | 2005-09-22 | Nof Corp | シクロスポリン製剤 |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| JP2008514702A (ja) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US7378391B2 (en) * | 2004-09-29 | 2008-05-27 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| US7825087B2 (en) * | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
| WO2006114776A1 (en) * | 2005-04-27 | 2006-11-02 | Kingspan Holdings (Irl) Limited | Surfactant for phenolic foam |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| WO2016205423A2 (en) | 2015-06-15 | 2016-12-22 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
| EP3824296B1 (en) | 2018-07-20 | 2026-04-01 | Lipocine Inc. | Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7012460A (cg-RX-API-DMAC10.html) | 1970-08-22 | 1972-02-24 | ||
| DE3225706C2 (de) | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen |
| DE3315805A1 (de) | 1983-04-30 | 1984-11-08 | Bayer Ag, 5090 Leverkusen | Wirkstoffzubereitungen |
| GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| FR2609631A1 (fr) | 1987-01-15 | 1988-07-22 | Sanofi Sa | Compositions liquides stables a base de bithionol |
| US6007840A (en) | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
| US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| DE3908047A1 (de) | 1989-03-13 | 1990-09-20 | Desitin Arzneimittel Gmbh | Hochdisperse pharmazeutische zusammensetzung |
| US5283229A (en) | 1989-12-11 | 1994-02-01 | Isp Investments Inc. | Delivery system for agricultural chemicals |
| US5266590A (en) | 1989-12-11 | 1993-11-30 | Isp Investments Inc. | Cold stabilization of aqueous microemulsions of a water-insoluble agriculturally active compound |
| US5389688A (en) | 1989-12-11 | 1995-02-14 | Isp Investments Inc. | Water based microemulsion formulations |
| US5110606A (en) | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
| CA2097707A1 (en) | 1991-02-12 | 1992-08-13 | Kolazi S. Narayanan | Stabilization of microemulsions using hydrophobic acid buffers |
| US5300529A (en) | 1991-02-12 | 1994-04-05 | Isp Investments Inc. | Stable, clear, efficacious aqueous microemulsion compositions containing a high loading of a water-insoluble, agriculturally active chemical |
| US6022853A (en) * | 1991-08-30 | 2000-02-08 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| GB9225540D0 (en) | 1992-12-07 | 1993-01-27 | Ici Plc | Cleaning compositions |
| JPH06293633A (ja) | 1993-04-05 | 1994-10-21 | Shin Etsu Chem Co Ltd | 水性腸溶性エマルジョンの製造方法 |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| FR2710535B1 (fr) | 1993-09-30 | 1995-11-24 | Gattefosse Ets Sa | Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion. |
| DE4337041A1 (de) | 1993-10-29 | 1995-05-04 | Henkel Kgaa | Verfahren zur Herstellung in Öl-in-Wasser-Emulsionen |
| WO1995022343A1 (en) | 1994-02-17 | 1995-08-24 | Shiseido Company, Ltd. | Cyclosporin-containing emulsion composition |
| MY129435A (en) | 1994-10-26 | 2007-04-30 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| US5691289A (en) | 1994-11-17 | 1997-11-25 | Kay Chemical Company | Cleaning compositions and methods of using the same |
| HU215966B (hu) | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| EP0825849A1 (en) | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
| SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
| DE19537836A1 (de) | 1995-10-11 | 1997-04-17 | Henkel Kgaa | Aerosolemulsionen |
| KR970064620A (ko) | 1996-03-05 | 1997-10-13 | 임성기 | 사이클로스포린-함유 외용약제 조성물 |
| DE19615271A1 (de) | 1996-04-18 | 1997-10-23 | Huels Chemische Werke Ag | Tensidhaltige Reinigungsmittel in Form einer Mikroemulsion |
| KR980008239A (ko) | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
| PT988046E (pt) * | 1997-01-30 | 2004-12-31 | Novartis Ag | Composicoes farmaceuticas sem oleo contendo ciclosporina a |
| HU228855B1 (en) * | 1997-03-12 | 2013-06-28 | Abbott Lab | Hydrophilic binary systems for the administration of cyclosporine |
| WO1998040051A1 (en) | 1997-03-12 | 1998-09-17 | Abbott Laboratories | Lipophilic binary systems for the administration of lipophilic compounds |
| US6028067A (en) | 1997-12-05 | 2000-02-22 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US6063762A (en) | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| WO1999029335A1 (en) | 1997-12-05 | 1999-06-17 | Chong Kun Dang Corp. | Pharmaceutical composition containing cyclosporin |
| US6284268B1 (en) | 1997-12-10 | 2001-09-04 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| NZ329929A (en) * | 1998-03-09 | 1999-10-28 | Bernard Charles Sherman | Pharmaceutical emulsion preconcentrate containing cyclosporin in a solvent system containing glycerides, propylene or polyethylene glycol, a surfactant and a co-surfactant |
| IL143604A0 (en) * | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
| GB9912476D0 (en) * | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
-
1999
- 1999-05-28 GB GBGB9912476.0A patent/GB9912476D0/en not_active Ceased
-
2000
- 2000-05-26 CN CN00808183A patent/CN1353613A/zh active Pending
- 2000-05-26 BR BR0011030-2A patent/BR0011030A/pt not_active Application Discontinuation
- 2000-05-26 HK HK02105374.3A patent/HK1045642B/en not_active IP Right Cessation
- 2000-05-26 RU RU2001133455/15A patent/RU2249461C2/ru not_active IP Right Cessation
- 2000-05-26 HU HU0201372A patent/HUP0201372A3/hu unknown
- 2000-05-26 PT PT00943742T patent/PT1181035E/pt unknown
- 2000-05-26 SK SK1722-2001A patent/SK285471B6/sk not_active IP Right Cessation
- 2000-05-26 DE DE60019100T patent/DE60019100T2/de not_active Expired - Fee Related
- 2000-05-26 CA CA002371247A patent/CA2371247A1/en not_active Abandoned
- 2000-05-26 DE DE10084671T patent/DE10084671T1/de not_active Withdrawn
- 2000-05-26 US US09/579,372 patent/US6432445B1/en not_active Expired - Fee Related
- 2000-05-26 CZ CZ20014214A patent/CZ20014214A3/cs unknown
- 2000-05-26 NZ NZ515154A patent/NZ515154A/en unknown
- 2000-05-26 TR TR2001/03276T patent/TR200103276T2/xx unknown
- 2000-05-26 AT AT00943742T patent/ATE291926T1/de not_active IP Right Cessation
- 2000-05-26 KR KR1020017013293A patent/KR20010111587A/ko not_active Ceased
- 2000-05-26 AU AU58100/00A patent/AU765935B2/en not_active Ceased
- 2000-05-26 JP JP2000620976A patent/JP2003500454A/ja active Pending
- 2000-05-26 GB GB0128277A patent/GB2367004B/en not_active Expired - Fee Related
- 2000-05-26 ES ES00943742T patent/ES2239605T3/es not_active Expired - Lifetime
- 2000-05-26 IL IL14618600A patent/IL146186A0/xx unknown
- 2000-05-26 MX MXPA01012222A patent/MXPA01012222A/es active IP Right Grant
- 2000-05-26 PL PL351593A patent/PL199591B1/pl not_active IP Right Cessation
- 2000-05-26 EP EP00943742A patent/EP1181035B1/en not_active Expired - Lifetime
- 2000-05-26 WO PCT/EP2000/004829 patent/WO2000072867A2/en not_active Ceased
-
2001
- 2001-11-23 ZA ZA200109658A patent/ZA200109658B/xx unknown
- 2001-11-27 NO NO20015785A patent/NO20015785L/no not_active Application Discontinuation
-
2002
- 2002-08-13 US US10/217,732 patent/US6767555B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765935B2 (en) | Substantially oil-free cyclosporin compositions | |
| CN100367930C (zh) | 可自发分散的n-苯甲酰基-星形孢菌素组合物 | |
| US20030082215A1 (en) | Fenofibrate galenic formulations and method for obtaining same | |
| JP2018027949A (ja) | 医薬組成物 | |
| AU755134B2 (en) | Microemulsion preconcentrates containing a piperidine substance P antagonist | |
| EP1715848B1 (en) | Microemulsion formulations comprising particular substance p antagonists | |
| MXPA06008856A (en) | Microemulsion formulations comprising particular substance p antagonists | |
| KR20070018003A (ko) | 특정 물질 ｐ 길항제를 포함하는 마이크로에멀젼 제제 |